2051 RINGWOOD AVENUE, SAN JOSE, CA
Material disclosure
Rani Therapeutics Enters $42.6M Securities Purchase Agreement
Reports Second Quarter 2025 Financial Results; Provides Corporate Update
News, Securities Holder Rights or Indentures, Legal Opinion, Material Contracts
News
Shareholder votes
News, Material Contracts
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Information Statement
Preliminary Information Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership